Survival advantage from Imatinib compared to the combination Interferon-{alpha} plus Cytarabine in chronic phase CML: historical comparison between tw

Posted by rob on April 27, 2006 under Uncategorized | Be the First to Comment

Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O’brien SG, So C, Massimini G, Guilhot F
Blood. 2006 Apr 20;

In the multinational IRIS study comparing imatinib to interferon plus cytarabine (IFN/AraC) in patients with newly diagnosed chronic-phase chronic myelogenous leukaemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyR) and improved progression free survival (PFS). However, because of a high early cross over rate to imatinib, survival benefit was not assessable. Here we report the result of a study comparing long term outcome of patients included in two prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/AraC in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation and overall survival were significantly higher with imatinib compared with IFN/AraC (P

Survival advantage from Imatinib compared to the combination Interferon-{alpha} plus Cytarabine in chronic phase CML: historical comparison between two phase III trials.

Add A Comment

You must be logged in to post a comment.

home top